Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers

There are currently no effective targeted therapies for KRAS mutant cancers. Therapeutic strategies that combine MEK inhibitors with agents that target apoptotic pathways may be a promising therapeutic approach. We investigated combining MEK and MDM2 inhibitors as a potential treatment strategy for...

Descripción completa

Detalles Bibliográficos
Autores principales: Hata, Aaron N, Rowley, Steve, Archibald, Hannah L, Gomez-Caraballo, Maria, Siddiqui, Faria M, Ji, Fei, Jung, Joonil, Light, Madelyn, Lee, Joon Sang, Debussche, Laurent, Sidhu, Sukhvinder, Sadreyev, Ruslan I, Watters, James, Engelman, Jeffrey A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5700857/
https://www.ncbi.nlm.nih.gov/pubmed/28783173
http://dx.doi.org/10.1038/onc.2017.258

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5700857/
https://www.ncbi.nlm.nih.gov/pubmed/28783173
http://dx.doi.org/10.1038/onc.2017.258

Ejemplares similares